Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Karvol Plus is an inhalation decongestant developed and marketed by Indoco Remedies. It is a combination product containing a blend of aromatic oils and natural substances, specifically camphor, chlorothymol, eucalyptol, terpinol, and menthol. Formulated as a soft gelatin capsule intended for inhalation rather than ingestion, it is used to provide symptomatic relief from nasal congestion caused by the common cold, respiratory infections, coryza, and bronchitis. The mechanism of action involves the release of vapors that soothe the respiratory tract, thin thickened mucus, and facilitate drainage, thereby easing breathing difficulties. It is indicated for use in adults and children as young as 3 months.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Karvol Plus.